Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of ETEC Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ages 18-45, inclusive.~* Provide written informed consent before initiation of any study procedures.~* Healthy as judged by the Principal Investigator (PI) and determined by medical history, physical examination, and medication history.~* Within 45 days of vaccination, have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, absolute neutrophil count (ANC), sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), partial thromboplastin time (PTT), International Normalized Ratio (INR), C-reactive protein (CRP), and fibrinogen as defined in Appendix B.~* Have normal screening laboratories for urine protein and urine glucose.~* Demonstrate comprehension of the protocol procedures and knowledge of study by passing a written examination (passing grade is at least 70 percent).~* Capable of understanding, consenting and complying with the entire study protocol including the inpatient period.~* Female subjects must be of non-childbearing potential, (as defined as surgically sterile or postmenopausal for more than 1 year), or if of childbearing potential must be practicing abstinence or using an effective licensed method of birth control (e.g., history of hysterectomy or tubal ligation; use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), cervical sponges, diaphragms, condoms with spermicidal agents, or must have a vasectomized partner) within 2 months of vaccination and must agree to continue such precautions during the study and for 30 days after the Day 28 study visit. Male subjects must agree not to father a child for 90 days after the Day 0 study visit. A woman is eligible if she is monogamous with a vasectomized male.~* Agrees not to participate in another clinical trial during the study period.~* Agrees not to donate blood to a blood bank for 12 months after receiving the vaccine.~Exclusion Criteria:~* Women who are pregnant or lactating or have a positive serum pregnancy test at screening or positive urine pregnancy test upon admission to inpatient facility.~* Abnormal Vital signs, defined as:~Hypertension (systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg) at rest on 2 separate days; or (heart rate \<55 at rest on 2 separate days) Respiratory rate \>17~* Temperature \>/= 38.0 C (100.4 F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within 7 days of administration of dmLT.~* Active positive Hepatitis B, C, and Human Immunodeficiency Virus (HIV) serologies.~* Have a positive urine drug screen.~* Subjects who are unwilling or unable to cease smoking for the duration of the inpatient stay.~* History of antimicrobial treatment in the 2 weeks before ingestion of dmLT.~* Received previous experimental E. coli, LT, or cholera vaccines or live E. coli or Vibrio cholerae challenges; or previous infection with cholera or diarrheagenic E. coli.~* Abnormal bowel habits as defined by fewer than 3 stools per week or more than 2 stools per day in the past 6 months.~* History of chronic gastrointestinal illness, including severe dyspepsia (mild or moderate heartburn or epigastric pain occurring no more than 3 times per week is permitted), lactose intolerance, or other significant gastrointestinal tract disease.~* Regular use (weekly or more often) of laxatives, anti-diarrheal, anti-constipation, or antacid therapy.~* History of major gastrointestinal surgery, excluding uncomplicated appendectomy or cholecystectomy.~* Long-term use of oral steroids, parenteral steroids, or high-dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (Nasal and topical steroids are allowed).~* Have a diagnosis of schizophrenia or other major psychiatric diagnosis.~* Receiving the following psychiatric drugs: aripiprazole, clozapine, ziprasidone, haloperidol, molindone, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, risperidone, mesoridazine, quetiapine, trifluoperazine, chlorprothixene, chlorpromazine, perphenazine, trifluopromazine, olanzapine, carbamazepine, divalproex sodium, lithium carbonate or lithium citrate.~NOTE: Subjects who are receiving a single antidepressant drug and are stable for at least 3 months before enrollment without de-compensating symptoms, will be allowed to be enrolled in the study.~* History of receiving immunoglobulin or other blood product within the 3 months before enrollment in this study.~* Traveled to certain Enterotoxigenic Escherichia coli (ETEC) endemic areas within the past 3 years or raised in a cholera or ETEC endemic area.~* Received any licensed vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) before enrollment in this study.~* An acute or chronic medical condition that, in the opinion of the investigator, would render ingestion of dmLT unsafe or would interfere with the evaluation of responses. This includes, but is not limited to: known or suspected immunodeficiency, known chronic liver disease, significant renal disease, unstable or progressive neurological disorders, history of diabetes, cancer (other than a healed skin lesion), heart disease (in the hospital for a heart attack, history of irregular heart beat or fainting caused by an irregular heart beat), unconsciousness (other than a single brief concussion), seizures (other than with fever when subject was a child \<5 years old), asthma requiring treatment with inhaler or medication in the prior 2 years, autoimmune disease or eating disorder, and transplant recipients.~* Received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month before enrollment in this study or expects to receive an experimental agent during the study.~* History of alcohol or drug abuse in the last 5 years.~* Planned to travel outside of the USA in the time between vaccination and 28 days following the vaccination.~* Unable to spend 4 days as an inpatient.~* Any condition that would, in the opinion of the Site Investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.~* Use of prescription and over-the-counter (OTC) medications that contain acetaminophen, aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs within 48 hours prior to receiving the investigational product.~* Use of prescription acid suppression medication or OTC antacids within 72 hours of investigational product administration.~* Subjects with autoimmune disorders, chronic inflammatory disorders or neurological disorders with a potential autoimmune correlation.~* Subjects who plan to travel to an ETEC endemic area during the long-term safety follow-up period (6 months) of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1: 5 mcg dmLT (Type: EXPERIMENTAL): 6 subjects to receive 5 micrograms (mcg) of dmLT vaccine.
- Cohort 4: 100 mcg dmLT (Type: EXPERIMENTAL): 6 subjects to receive 100 mcg of dmLT vaccine.
- Cohort 2: 25 mcg dmLT (Type: EXPERIMENTAL): 6 subjects to receive 25 mcg of dmLT vaccine.
- Cohort 3: 50 mcg dmLT (Type: EXPERIMENTAL): 6 subjects to receive 50 mcg of dmLT vaccine.
- Cohort 5: 50 mcg or 100 mcg dmLT (Type: EXPERIMENTAL): 12 subjects randomized, double-blinded, to receive either 50 mcg or 100 mcg of dmLT vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).